Gibson Dunn Advised Dianthus Therapeutics on $288 Million Offering of Common Stock and Pre-Funded Warrants
Gibson Dunn provided advice on Dianthus therapies, Inc.’s $288 million offering of common stock and pre-funded warrants. Dianthus Therapeutics, Inc. is a clinical-stage biotechnology firm committed to developing the next generation of antibody complement therapies to treat severe autoimmune illnesses.